| Literature DB >> 32106111 |
Paul Fellinger1, Peter Wolf1, Lorenz Pfleger1,2, Patrik Krumpolec2, Martin Krssak1,2, Kristaps Klavins3, Stefan Wolfsberger4, Alexander Micko4, Patricia Carey3, Bettina Gürtl3, Greisa Vila1, Wolfgang Raber1, Clemens Fürnsinn1, Thomas Scherer1, Siegfried Trattnig2, Alexandra Kautzky-Willer1, Michael Krebs1, Yvonne Winhofer1.
Abstract
Patients with active acromegaly (ACRO) exhibit low hepatocellular lipids (HCL), despite pronounced insulin resistance (IR). This contrasts the strong association of IR with nonalcoholic fatty liver disease in the general population. Since low HCL levels in ACRO might be caused by changes in oxidative substrate metabolism, we investigated mitochondrial activity and plasma metabolomics/lipidomics in active ACRO. Fifteen subjects with ACRO and seventeen healthy controls, matched for age, BMI, sex, and body composition, underwent 31P/1H-7-T MR spectroscopy of the liver and skeletal muscle as well as plasma metabolomic profiling and an oral glucose tolerance test. Subjects with ACRO showed significantly lower HCL levels, but the ATP synthesis rate was significantly increased compared with that in controls. Furthermore, a decreased ratio of unsaturated-to-saturated intrahepatocellular fatty acids was found in subjects with ACRO. Within assessed plasma lipids, lipidomics, and metabolomics, decreased carnitine species also indicated increased mitochondrial activity. We therefore concluded that excess of growth hormone (GH) in humans counteracts HCL accumulation by increased hepatic ATP synthesis. This was accompanied by a decreased ratio of unsaturated-to-saturated lipids in hepatocytes and by a metabolomic profile, reflecting the increase in mitochondrial activity. Thus, these findings help to better understanding of GH-regulated antisteatotic pathways and provide a better insight into potentially novel therapeutic targets for treating NAFLD.Entities:
Keywords: Endocrinology; Fatty acid oxidation; Insulin; Metabolism; growth factors
Mesh:
Substances:
Year: 2020 PMID: 32106111 PMCID: PMC7141383 DOI: 10.1172/jci.insight.134638
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708